Kura Oncology Profile

15.55
USD 0.75  5.07%
8%
79%

Kura Oncology exotic insider transaction detected

Kura Oncology Inc insider trading alert for general transaction of common stock by Thomas Malley, the corporate stakeholder, on March 23, 2018. This event was filed by Kura Oncology Inc with SEC on 2015-10-14. Initial filing of beneficial ownership - SEC Form 3 [view details]   

Kura Oncology Summary

Kura Oncology (KURA) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 31 people. Kura Oncology is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 582.84 M. Kura Oncology conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 32.56 M outstanding shares of which 2.35 M shares are now shorted by private and institutional investors with about 7.05 trading days to cover. Kura Oncology currently holds about 93.14 M in cash with (28.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.17.
Check Kura Oncology Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Below OddsHorizonTargetAbove Odds
about 5.94%30 days 15.55  under 95%
Based on normal probability distribution, the odds of Kura Oncology to move above current price in 30 days from now is under 95% (This Kura Oncology probability density function shows the probability of Kura Oncology Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Alethea Capital Management LlcCommon Shares180.6 K3.4 M
Capital Impact Advisors LlcCommon Shares79.8 K1.5 M
View Kura Oncology Diagnostics

Selected Kura Oncology Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Kura Oncology Against Markets

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
< 4% 
Equity ratings for Kura Oncology are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. The company was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in USA and traded on NASDAQ. It employs 31 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameKura Oncology
ChairmanTroy WilsonView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
LocationCALIFORNIA, U.S.A
Business Address3033 Science Park Road
ExchangeNASDAQ
CIK Number01422143.0
CUSIP50127T109
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.kuraoncology.com
Contact Number858 500 8800
CurrencyUSD - US Dollar

Recommendations

Kura Oncology Analyst Recommendations
Target PriceAdvice# of Analysts
16.5Strong Buy2Odds
Kura Oncology current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Kura Oncology Analyst Advice  

Earnings

Kura Oncology Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.39March 16, 2017
Kura Oncology normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

Kura Oncology Corporate Directors
Steven Stein Director
Faheem Hasnain Independent Director
Thomas Malley Director
Please see also Stocks Correlation. Please also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.